Clinical potential of apremilast in the treatment of psoriatic arthritis
Alberto Cauli, Giovanni Porru, Matteo Piga, Alessandra Vacca, Grazia Dessole, Alessandro MathieuRheumatology Unit, Department of Medical Sciences, Policlinico of University of Cagliari, Monserrato, ItalyAbstract: Psoriatic arthritis (PsA) is a frequent chronic inflammatory disease characterized by j...
| Published in: | ImmunoTargets and Therapy |
|---|---|
| Main Authors: | Cauli A, Porru G, Piga M, Vacca A, Dessole G, Mathieu A |
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2014-06-01
|
| Subjects: | |
| Online Access: | https://www.dovepress.com/clinical-potential-of-apremilast-in-the-treatment-of-psoriatic-arthrit-peer-reviewed-article-ITT |
Similar Items
Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis
by: Haddad A, et al.
Published: (2023-10-01)
by: Haddad A, et al.
Published: (2023-10-01)
Clinical experience with apremilast for psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2018-09-01)
by: E. Yu. Loginova, et al.
Published: (2018-09-01)
Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study
by: Vinod Chandran, et al.
Published: (2024-02-01)
by: Vinod Chandran, et al.
Published: (2024-02-01)
APREMILAST: AN UPDATE ON ITS EFFICACY AND SAFETY DURING LONG-TERM TREATMENT OF PATIENTS WITH PSORIATIC ARTHRITIS
by: Yu. L. Korsakova, et al.
Published: (2018-11-01)
by: Yu. L. Korsakova, et al.
Published: (2018-11-01)
Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study
by: Andrea Becciolini, et al.
Published: (2023-02-01)
by: Andrea Becciolini, et al.
Published: (2023-02-01)
Apremilast: target synthetic drug for the treatment of psoriatic arthritis and psoriasis
by: Yu. L. Korsakova, et al.
Published: (2018-07-01)
by: Yu. L. Korsakova, et al.
Published: (2018-07-01)
Apremilast generic for the treatment of active psoriatic arthritis: A single-center real-life experience from India
by: Sanjiv Amin, et al.
Published: (2020-01-01)
by: Sanjiv Amin, et al.
Published: (2020-01-01)
Clinical and molecular insights into cardiovascular disease in psoriatic patients and the potential protective role of apremilast
by: Nuria Barbarroja, et al.
Published: (2024-08-01)
by: Nuria Barbarroja, et al.
Published: (2024-08-01)
Psoriatic arthritis with atypical manifestations
by: Ivna Tomaš, et al.
Published: (2023-01-01)
by: Ivna Tomaš, et al.
Published: (2023-01-01)
The efficacy and safety of apremilast in patients with psoriatic arthritis concurrent with comorbidity in clinical practice
by: E. Yu. Loginova, et al.
Published: (2019-07-01)
by: E. Yu. Loginova, et al.
Published: (2019-07-01)
The place of a phosphodiesterase 4 inhibitor in the treatment strategy for psoriatic arthritis
by: V. I. Mazurov, et al.
Published: (2018-04-01)
by: V. I. Mazurov, et al.
Published: (2018-04-01)
Use of phosphodiesterase 4 inhibitor in patients with psoriatic arthritis
by: V. I. Mazurov, et al.
Published: (2017-04-01)
by: V. I. Mazurov, et al.
Published: (2017-04-01)
Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis
by: Hagberg KW, et al.
Published: (2020-02-01)
by: Hagberg KW, et al.
Published: (2020-02-01)
New opportunities in the treatment of psoriasis and psoriatic arthritis
by: A. A. Kubanov, et al.
Published: (2019-01-01)
by: A. A. Kubanov, et al.
Published: (2019-01-01)
Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic
by: Ashis K. Das, et al.
Published: (2023-07-01)
by: Ashis K. Das, et al.
Published: (2023-07-01)
Phosphodiesterase-4 inhibitor in the treatment of psoriasis and psoriatic arthritis
by: O. Yu. Olisova, et al.
Published: (2019-07-01)
by: O. Yu. Olisova, et al.
Published: (2019-07-01)
Current views on the pharmacotherapy of psoriatic arthritis
by: G. G. Taradin, et al.
Published: (2016-01-01)
by: G. G. Taradin, et al.
Published: (2016-01-01)
Self-Nanoemulsifying Drug Delivery System (SNEDDS) of Apremilast: In Vitro Evaluation and Pharmacokinetics Studies
by: Ahad S. Abushal, et al.
Published: (2022-05-01)
by: Ahad S. Abushal, et al.
Published: (2022-05-01)
Commentary: Successful treatment of refractory palmoplantar pustular psoriasis with apremilast: a case series
by: Madison Hackley, et al.
Published: (2023-10-01)
by: Madison Hackley, et al.
Published: (2023-10-01)
Effects on Lipid Profile after One Year of Apremilast Therapy in Patients with Psoriasis: A Monocentric Experience
by: Prisca Guerra, et al.
Published: (2024-03-01)
by: Prisca Guerra, et al.
Published: (2024-03-01)
THE EFFICACY AND SAFETY OF THE NEW DRUG APREMILAST FOR THE TREATMENT OF PSORIASIS AND PSORIATIC ARTHRITIS
by: Yu. L. Korsakova, et al.
Published: (2016-12-01)
by: Yu. L. Korsakova, et al.
Published: (2016-12-01)
Dramatic response of cutaneous, nail, and joint symptoms of psoriasis to apremilast
by: Meghana Bathina, et al.
Published: (2019-01-01)
by: Meghana Bathina, et al.
Published: (2019-01-01)
CLINICAL HETEROGENEITY OF EARLY PSORIATIC ARTHRITIS
by: V. V. Badokin, et al.
Published: (2016-12-01)
by: V. V. Badokin, et al.
Published: (2016-12-01)
IS PSORIATIC ARTHRITIS REALLY PSORIATIC?
by: Sh. F. Erdes
Published: (2014-12-01)
by: Sh. F. Erdes
Published: (2014-12-01)
Psoriatic arthritis: genetics and pathogenesis
by: A. Mathieu, et al.
Published: (2012-06-01)
by: A. Mathieu, et al.
Published: (2012-06-01)
Clinical and instrumental characteristics of axial psoriatic arthritis in combination with hyperuricemia
by: Yu. L. Korsakova, et al.
Published: (2024-08-01)
by: Yu. L. Korsakova, et al.
Published: (2024-08-01)
Nail disease in psoriatic arthritis. Data from the Russian Psoriatic Arthritis Registry
by: E. E. Gubar, et al.
Published: (2021-10-01)
by: E. E. Gubar, et al.
Published: (2021-10-01)
Psoriatic arthritis treatment to the target: a consensus, evidence-based clinical practice recommendations for the management of psoriatic arthritis and its concomitant clinical manifestations
by: Yasser El Miedany, et al.
Published: (2022-06-01)
by: Yasser El Miedany, et al.
Published: (2022-06-01)
Difficult-to-treat psoriatic arthritis. Data from the All-Russian registry of patients with psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2024-10-01)
by: E. Yu. Loginova, et al.
Published: (2024-10-01)
ENTHESITIS AND PSORIATIC ONYCHOPATHY AS A FACTOR FOR PREDICTION OF PSORIATIC ARTHRITIS IN PSORIASIS
by: Tatyana G. Sidorcika, et al.
Published: (2018-04-01)
by: Tatyana G. Sidorcika, et al.
Published: (2018-04-01)
From Psoriasis to Psoriatic Arthritis: Decoding the Impact of Treatment Modalities on the Prevention of Psoriatic Arthritis
by: Abdulla Watad, et al.
Published: (2024-06-01)
by: Abdulla Watad, et al.
Published: (2024-06-01)
Clinical profiling of psoriatic arthritis: an observational cross-sectional study from Karnataka Psoriatic Arthritis Cohort
by: Chanakya Kodishala, et al.
Published: (2022-01-01)
by: Chanakya Kodishala, et al.
Published: (2022-01-01)
The use of guselkumab in psoriatic arthritis: evidence from real clinical practice
by: N. V. Nekrasova, et al.
Published: (2021-12-01)
by: N. V. Nekrasova, et al.
Published: (2021-12-01)
Psoriatic erythroderma: comparative patient profile and association with psoriatic arthritis
by: Elena V. Bogdanova
Published: (2023-01-01)
by: Elena V. Bogdanova
Published: (2023-01-01)
Updated international recommendations (EULAR, 2023) for the treatment of psoriatic arthritis
by: Yu. L. Korsakova, et al.
Published: (2024-11-01)
by: Yu. L. Korsakova, et al.
Published: (2024-11-01)
Psoriatic arthritis: imaging techniques
by: E. Lubrano, et al.
Published: (2012-06-01)
by: E. Lubrano, et al.
Published: (2012-06-01)
Axial Disease in Psoriatic Arthritis: A Challenging Domain in Clinical Practice
by: Lucía Alascio, et al.
Published: (2024-07-01)
by: Lucía Alascio, et al.
Published: (2024-07-01)
Psoriasis and Psoriatic Arthritis in ChildhoodPsoriasis and Psoriatic Arthritis in Childhood
by: Nikolay N. Murashkin, et al.
Published: (2020-12-01)
by: Nikolay N. Murashkin, et al.
Published: (2020-12-01)
How Are We Addressing Axial Psoriatic Arthritis in Clinical Practice?
by: Xabier Michelena, et al.
Published: (2024-10-01)
by: Xabier Michelena, et al.
Published: (2024-10-01)
Methotrexate in a psoriatic arthritis patient
by: K. V. Aleksanyan, et al.
Published: (2016-09-01)
by: K. V. Aleksanyan, et al.
Published: (2016-09-01)
Similar Items
-
Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis
by: Haddad A, et al.
Published: (2023-10-01) -
Clinical experience with apremilast for psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2018-09-01) -
Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study
by: Vinod Chandran, et al.
Published: (2024-02-01) -
APREMILAST: AN UPDATE ON ITS EFFICACY AND SAFETY DURING LONG-TERM TREATMENT OF PATIENTS WITH PSORIATIC ARTHRITIS
by: Yu. L. Korsakova, et al.
Published: (2018-11-01) -
Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study
by: Andrea Becciolini, et al.
Published: (2023-02-01)
